MedTrace Logo

Effect of C21 on Forearm Blood Flow

NCT05277922 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-04-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.

Conditions

  • Study Vasodilatory Effects of C21

Interventions

DRUG

C21

C21 in ascending doses of 15, 50, 150, 500 and 1000 µg

DRUG

Sodium Nitroprusside

Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control

Sponsors & Collaborators

  • CTC Clinical Trial Consultants AB

    collaborator INDUSTRY

  • Vicore Pharma AB

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2022-05-11
Completion
2022-05-18

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05277922 on ClinicalTrials.gov